玉溪妇科无痛人流医院(玉溪做人流一般需要多少钱) (今日更新中)

The first round of the NFL Draft got underway Thursday evening and Oklahoma quarterback Baker Mayfield was selected as the first overall draft pick by the Cleveland Browns. Mayfield will likely take over as Cleveland's starting quarterback in the fall after the Browns finished the 2017 season with a winless 0-16 record. Mayfield was a three-year starter at Oklahoma after starting one season for Texas Tech. He threw for 131 touchdowns over his four collegiate years, which is fourth all time in NCAA Division I history. According to most NFL Draft experts, five college quarterbacks will likely be selected in the first round on Thursday. The group includes USC's Sam Darnold, Oklahoma's Baker Mayfield, Wyoming's Josh Allen, UCLA's Josh Rosen and Louisville's Lamar Jackson.  807

The Food and Drug Administration (FDA) has cleared the way for a generic version of EpiPen to be created.The FDA’s approval for a generic version, which will be created by Teva Pharmaceuticals, could help alleviate issues like high cost for the life-saving allergy medication.Two year ago, prices for EpiPens skyrocketed, as manufacturer Mylan raised rates from less than 0 for a two-pack to close to 0.But new action by the FDA paves the way for a generic form of the drug, so pharmacies can now offer a generic form to customers, without having to call the doctor to write a new prescription."Oh, it's a huge deal for consumers because the current price is astronomical for a drug that you hope never to use,” says Gerard Anderson, a professor at Johns Hopkins University who has testified about drug prices before Congress.EpiPens have been experiencing shortages, made even worse by the back-to-school orders placed by parents. Anderson says this move to create generic forms should help with the supply and bring prices down.“You’re still gonna get the same drug administered,” says Anderson of the generic forms of the medication. “And so, as a consumer, as a parent, I would choose a less expensive alternative.” 1233

The Farmers’ Almanac has released its wintertime forecast for 2020-21 on Monday, and said it is expecting a cold, snowy winter for much of the United States.Where it is normally cold enough to snow in the US, the Farmers’ Almanac predicts above average snowfall in most areas.From the Mississippi River to the east, the US is expected to see below normal temperatures. The northern Plains and Rockies will also see colder than average temperatures according to the almanac.The Pacific Northwest could see some of the most pleasant weather of the winter in the US, with mild and dry conditions expected there. The southwest is expected to see normal temperatures.Snow lovers, before you get too excited by the forecast, know that long-term forecasts have a tendency to be off.Last year, the Farmers’ Almanac predicted a “Polar Coaster Winter” for much of the US. Those predictions did not come to light, especially in the Midwest, which had a well above average winter.Still, the Farmers’ Almanac stands by its projections."Preparing people for the unexpected is more important than ever," states editor Peter Geiger, Philom. "Our job as editors of the Farmers' Almanac is to pass down valuable tips and advice to help our readers thrive, no matter the obstacles."To see more detail on the Almanac's forecast, click here. 1328

The death toll from a series of wildfires in western states rose sharply Thursday evening, and officials expect more casualties and damage in the coming days.A total of 17 people have been killed in wildfires in California, Oregon and Washington in recent days. More than 100 fires are currently burning throughout 13 western states.On Thursday evening, officials with the Butte County Sheriff's Office in California announced that seven more people had died in what is now known as the North Complex Fire, according to ABC News. That brings the death toll from that particular fire up to 10, with 16 people still missing.ABC News also reports that one other person died Thursday in the Slater Fire, which is currently burning in Siskiyou County, California.A total of four people have been killed in a series of wildfires in Oregon in recent days. One person died Thursday in the Almeda Fire in the southern part of the state, bringing the total death toll to two. Two others died in a wildfire near Salem on Wednesday.In Washington, a 1-year-old boy was killed by the Cold Springs Fire, which is currently burning in the northeast part of the state.USA Today reports that more than 500,000 people in Oregon have been forced to evacuate due to the wildfires — more than 10% of the state's population. Many of the fires burning in Oregon are currently 0% contained — further threatening forest, 900,000 acres of which have already been burned in the state. That's more than double what typically burns in an entire year.“We have never seen this amount of uncontained fire across the state,” Oregon Gov. Kate Brown said Thursday.The New York Times reports that officials in California, Oregon and Washington are struggling to find the manpower for fighting the fires, as nearby states deal with their own outbreaks of wildfires.On Thursday evening, President Donald Trump approved an emergency declaration for the wildfires in Oregon, which allows FEMA and the Department of Homeland Security to coordinate disaster relief efforts. 2038

The Food and Drug Administration on Wednesday authorized the first rapid coronavirus test that doesn’t need any special computer equipment to get results.The 15-minute test from Abbott Laboratories will sell for , giving it a competitive edge over similar tests that need to be popped into a small machine. The size of a credit card, the self-contained test is based on the same technology used to test for the flu, strep throat and other infections.It’s the latest cheaper, simpler test to hit the U.S. market, providing new options to expand testing as schools and businesses struggle to reopen and flu season approaches. The FDA also recently greenlighted a saliva test from Yale University that bypasses some of the supplies that have led to testing bottlenecks.Both tests have limitations and neither can be done at home. Several companies are developing rapid, at-home tests, but none have yet won approval. Abbott’s new test still requires a nasal swab by a health worker, like most older coronavirus tests. The Yale saliva test eliminates the need for a swab, but can only be run at high-grade laboratories.And in general, rapid tests like Abbott’s are less accurate than lab-developed tests. The FDA said in a statement announcing the decision that negative results with Abbott’s test may need to be confirmed with a lab test in some cases. The agency granted Abbott’s test an emergency use authorization late Wednesday for patients with suspected COVID-19.The two additions should help expand the number of available tests. The U.S. is now testing about 690,000 people per day, down from a peak of 850,000 daily tests late last month. Many public health experts believe the country will soon need to test vastly more people to find those who are infected, isolate them and contain the virus.The FDA noted that Abbott’s test could be used in a doctor’s office, emergency room or some schools. “Given the simple nature of this test, it is likely that these tests could be made broadly available,” the FDA said.Since the start of the pandemic, nasal swab tests that are sent to a lab have been the standard for COVID-19 screening. While considered highly accurate, the tests rely on expensive, specialized machines and chemicals. Shortages of those supplies have led to repeated delays in reporting results, especially during a spike in cases last month.Government and health experts view rapid tests that can be run outside the laboratory system as key to boosting capacity.“Those screening tests are what we need in schools, workplaces and nursing homes in order to catch asymptomatic spreaders,” said Dr. Jonathan Quick of the Rockefeller Foundation, in an interview earlier this month. The nonprofit group has called for the U.S. to conduct about 4 millions per day by October, mostly rapid, point-of-care tests.Abbott’s BinaxNOW is the fourth rapid test that detects COVID-19 antigens, proteins found on the surface of the coronavirus, rather than the virus itself. It’s considered a faster, though sometimes less precise, screening method. The other tests need to be inserted into a small machine.Inside the Abbott test is a specially coated strip that interacts with COVID-19 antigens. The patient’s nasal swab is inserted into the card and a few drops of a chemical solution are added. Markings appear on the card to indicate whether the sample is positive or negative — much like a pregnancy test.Two other makers of antigen tests — Quidel and Becton Dickinson have said they haven’t been able to meet demand for the tests. A third, LumiraDx, plans to begin shipping its recently approved antigen tests by the end of this month. Abbott expects to begin shipping tests in September, reaching 50 million tests a month in October.The influx of antigen tests will go a long way toward meeting the Trump administration’s projection that 90 million COVID-19 tests a month will be available by September if needed. But U.S. “testing czar” Adm. Brett Giroir has stressed that the U.S. can contain the outbreak with far fewer tests.“That’s the capacity ... we do not need that many tests to safely and sensibly reopen,” Giroir told reporters on a recent call. He pointed to several key indicators that have been falling, including new infections and hospitalizations, even as testing has slowed.Earlier this month, the FDA authorized Yale’s saliva-based test, which is expected to cut the time and cost compared with similar tests. It’s the fifth COVID-19 saliva tests OK’d by regulators. All require lab processing.Developed by Yale’s School of Public Health, SalivaDirect can use any sterile container to collect a sample, not the special tube needed with earlier tests, and requires less chemicals. Outside experts welcomed the new approach but noted its limitations.“It’s not a rapid test, it’s a laboratory-based test that will still be prone to the same massive delays as any other test,” said Dr. Michael Mina of Harvard University.___Follow Matthew Perrone on Twitter: @ AP_FDAwriter.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 5201

来源：资阳报